Nachrichten zur Inventiva S.A. Aktie

Inventiva S.A.: Piper Sandler sieht enormes Potenzial in Lanifibranor zur Behandlung der metabolischen Dysfunktions-assoziierten Steatohepatitis!

Inventiva S.A. (IVA) ist ein biopharmazeutisches Unternehmen, das sich auf orale niedermolekulare Therapien für die Behandlung von Patienten mit MASH…

Inventiva secures the €116 million second tranche of its structured financing of up to €348 million

Daix (France), New York City (New York, United States), May 5, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva”…

Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024

Daix (France), Long Island City (New York, United States), October 21, 2024 - Inventiva (Euronext Paris and Nasdaq: IVA)…

Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants

Daix (France), Long Island City (New York, United States), October 14, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva”…

Inventiva announces a €20.1 million issuance of royalty certificates

Daix (France), Long Island City (New York, United States), July 18, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva”…

Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position

Daix (France), Long Island City (New York, United States), July 5, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or…

Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor

Daix (France), Long Island City (New York, United States), May 13, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a…

Inventiva S.A. (IVA) Q4 2023 Earnings Call Transcript

…

dpa-AFX ProFeed